Aminoglutethimide dose and hormone suppression in advanced breast cancer
- 15 April 1983
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 19 (4) , 493-498
- https://doi.org/10.1016/0277-5379(83)90112-8
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Aminoglutethimide for the treatment of advanced postmenopausal breast cancerEuropean Journal of Cancer and Clinical Oncology, 1983
- Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast CancerJournal of Clinical Endocrinology & Metabolism, 1982
- Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.BMJ, 1981
- Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.Journal of Clinical Investigation, 1980
- Serum Aminoglutethimide Levels: Studies of Serum Half‐Life, Clearance, and Patient ComplianceThe Journal of Clinical Pharmacology, 1979
- Stereoselective Inhibition of Aromatase by Enantiomers of Aminoglutethimide*Endocrinology, 1979
- Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*Journal of Clinical Endocrinology & Metabolism, 1978
- Medical Adrenalectomy with AminoglutethimideAnnals of Surgery, 1978
- Assessment of response to therapy in advanced breast cancerPublished by Elsevier ,1977
- Aminoglutethimide (Elipten-Ciba) as an Inhibitor of Adrenal Steroidogenesis: Mechanism of Action and Therapeutic TrialJournal of Clinical Endocrinology & Metabolism, 1967